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Research in tumour-induced immunosuppression has recently
focused on alterations in the T-cell receptor complex (TCR/CD3)
(Frydecka et al, 1998). Antigen recognition is mediated by the
TCR alfa beta chains. The TCR-associated complex of CD3 trans-
membrane proteins provide a signal to direct the transport of the
assembled TCR/CD3 complex from the Golgi apparatus to the cell
surface and is involved in the transduction of activation signals
following engagement of the TCR. A key role in this process is
played by the zeta chain (Weissman et al, 1988; Irving and Weiss,
1991). 
Natural killer (NK) cells express the zeta chain as a heterodimer
linked to CD16 (Anderson et al, 1990), and the zeta chain seems to
have a role in signal transduction within the NK population. This
is analogous to what has been observed in T cells and may be crit-
ical for the induction of NK cell-mediated antibody-dependent
cytotoxicity (Vivier et al, 1991). 
The consequences of reduced zeta chain levels are likely to be
functionally important because the phosphorylation of the immu-
noreceptor tyrosine-based activation motifs on the intracyto-
plasmic component of the zeta chain by protein kinases is an
important early event in T-cell and NK-cell activation. Reduced
levels of zeta chains result in a relative lack of tyrosine residues for
phosphorylation and a reduced recruitment and phosphorylation 
of downstream signal-transducing molecules, such as ZAP-70,
leading to a failure of T- and NK-cell activation, proliferation and
cytokine production (Musci et al, 1997). Alterations in the signal
transduction machinery within T cells may hamper effective acti-
vation upon recognition of tumour-associated antigens (Kiessling
et al, 1999; Whiteside, 1999). 
The first studies on the expression of the CD3 zeta chain in
human cancer were reported by Nakagomi et al (1993) in colo-
rectal carcinoma and Finke et al (1993) in renal cell carcinoma.
After these initial studies, decreased levels of CD3 zeta and NK
zeta expression were reported in several solid and haematological
malignancies (reviewed in Frydecka et al, 1998; Kiessling et al,
1999; Whiteside, 1999). 
Here we have extended our previous study on zeta chain expres-
sion in subpopulations of peripheral blood T cells (PBT) and NK
cells in Hodgkin’s disease (HD) patients (Frydecka et al, 1999).
The aim was to investigate whether stimulation with anti-CD3,
anti-CD3+rIL-2 can overcome the previously observed impaired
zeta chain expression in CD4+, CD8+ and CD56+ cells in the active
disease and CD8+ cells in clinical remission and its effect on IL-2
production. According to our knowledge, no such studies have
been reported so far. 
MATERIALS AND METHODS 
Patients 
The study was performed in 20 patients in the active phase of HD
(stages III and IV) aged 24–68 years (mean 42.0), 15 patients in
clinical remission aged 25–60 years (mean 43.0) and 20 age- and
sex-matched healthy subjects. 
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classification, was assessed using standard procedures (Carbone 
et al, 1971). Studies were carried out with the approval of the
ethical committee. 
Flow cytometric analysis 
Peripheral blood mononuclear cells (PBMC) were separated by
buoyant density gradient centrifugation on Gradisol L (Kutno,
Poland) from freshly drawn peripheral venous blood, washed 3
times with 0.9% saline solution. All the experiments were carried
out by double labelling with anti-CD4, anti-CD8, anti-CD56
monoclonal antibody (MoAb) (Becton-Dickinson, San Jose, CA)
and CD3 zeta (TIA-2) MoAb directed against the cytoplasmic
domain of the zeta chain (Coulter, Miami, F1). The cells were
fixed and permeabilized according to the method described by
Anderson et al (1980).
Briefly, the cells were incubated for 10 min at room temperature
with 2 ml of a mixture of 1 ml 4% paraformaldehyde in phosphate-
buffered saline (PBS) and 1 ml of a 1:10 dilution of FACS lysing
solution (Becton-Dickinson) in distilled water. The cells were
washed with PBS containing 0.5% Tween 20 and incubated for 20
min with AB serum and anti-zeta chain MoAb. Cells were then
washed using PBS containing 0.5% Tween 20 and incubated with
goat-anti-mouse FITC, washed twice with PBS/Tween 20 and
resuspended for 5 min in mouse serum diluted to 1:2000. Cells
were then incubated for 20 min with phycoerythrin-conjugated
MoAB to CD4, CD8 and CD56, washed twice in PBS/Tween 20,
resuspended in PBS, and analysed by flow cytometry using
FACScalibur flow cytometer (Becton-Dickinson). Negative
controls were always used, omitting the MoAb as well as incu-
bating the cells with mouse Ig of the same isotype as MoAbs
conjugated with fluoresceine or phycoerythrin.
The results were expressed as the proportions of CD4+, CD8+
and CD56+ cells co-expressing the zeta chain. At least 10 000
events per sample were analysed in double staining analysis.
Culture conditions 
PBMC were resuspended to 1 ´ 106 PBMC ml–1 in RPMI 1640
supplemented with 10% fetal calf serum. Cells were stimulated
with 10 ng of anti-CD3 MoAb (Ortho, Neckargemund, Germany)
and 10 ng ml–1 of anti-CD3+ 500 U ml–1 of rIL-2 (Eurocetus,
Amsterdam, the Netherlands). Control cultures without stimulants
were included in each experiment. The cultures were incubated at
37˚C in a humidified atmosphere containing 5% CO2 for 72 h.
Culture supernatants were stored at –70˚C until the time of testing. 
Measurement of IL-2 level 
IL-2 concentrations were assessed in duplicate, applying a sand-
wich enzyme immunoassay ELISA (R&D Systems, Wiesbaden,
Germany). The values were expressed as nanograms per millilitre
(ng ml–1) relative to a set of standards supplied with the kit. Basal
levels of cytokine observed after culture with media and stimu-
lants alone were subtracted from the results obtained after PBL
stimulation. 
RESULTS 
The proportions of lymphocyte co-expression of CD4 and the zeta
chain were 61% ± 6%; 78% ± 9%; 85% ± 10% in the active
disease, clinical remission and the control group, respectively
(Table 1). The values for patients with active disease were statisti-
cally lower (P = 0.005) compared with control group (Table 1).
Stimulation with anti-CD3 did not significantly change the
percentage of doubly stained cells. Co-stimulation with rIL-2
significantly increased the percentages of CD4+/zeta+ cells in
patients with active disease (P = 0.05), in clinical remission 
(P = 0.05) and healthy subjects (P = 0.05) (Table 1). However, the
proportion of CD4+/zeta+ cells in patients with active disease
remained lower compared with the healthy subjects (P = 0.002)
(Table 1). 
The proportions of CD8+/zeta+ were 60% ± 8%, 69% ± 10% and
80% ± 10% in active disease, remission and healthy subjects,
respectively (Table 2). The mean value of CD8+/zeta+ cells in
active phase and clinical remission remained statistically lower 
(P = 0.05) compared with healthy subjects (Table 2). Anti-CD3 
stimulation had no effect on zeta-chain expression; co-stimulation
with rIL-2 increased but did not normalize the proportion of
CD8+/zeta+ cells in active disease, but normalized in clinical
remission (Table 2). 
The proportions of CD56+/zeta+ cells were 70% ± 8%, 81% ±
12% and 85% ± 10% in the active disease, clinical remission and
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Table 1 CD3/zeta chain expression in unstimulated, anti-CD3 MoAb stimulated and anti-CD3 MoAb + rIL-2 stimulated peripheral blood
CD4+ cells from patients with Hodgkin’s disease in active phase of HD, complete remission and healthy controls 
Unstimulated Anti-CD3 MoAb  Anti-CD3 P
stimulated MoAb+IL-2
stimulated
Active disease n = 20 61% ± 6% 70% ± 8% 74% ± 10% I:VII = 0.05
(I) (IV) (VII) I:IV NS 
IV:VII NS 
Clinical remission n = 15 78% ± 9% 85% ± 4% 90% ± 12% II:VIII = 0.05 
(II) (V) (VIII) II:V NS
V:VIII NS 
Healthy controls n = 20 85% ± 10% 89% ± 12% 94% ± 10% III:IX = 0.05 
(III) (VI) (IX) III:VI NS 
VI:IX NS 
P I:III = 0.005 IV:VI = 0.006 VII:IX = 0.002 
I:II NS, IV:V NS VII:VIII NS, 
II:III NS V:VI NS VIII:IX NS healthy subjects, respectively. The decreased proportion of
CD56+/zeta+ cells normalized in clinical remission (Table 3).
Stimulation with anti-CD3 had no effect on zeta-chain expression
in CD56+ cells, but co-stimulation with rIL-2 significantly
increased the mean proportion of CD56+/zeta+ cells in the active
disease (P = 0.02), though this value (81% ± 10%) was signifi-
cantly lower than that obtained from healthy subjects (92% ± 8%)
(P = 0.05) (Table 3). 
The production of IL-2 by anti-CD3+rIL-2-stimulated PBMC
was severely impaired in patients with active HD compared with
patients in remission (P = 0.05) and healthy subjects (P = 0.02). 
In clinical remission, the mean value of the IL-2 concentration 
was not statistically different from that obtained in the controls
(Figure 1). 
DISCUSSION 
Only limited data are available concerning the effects of IL-2 on the
expression of the zeta chain obtained from patients with cancer.
Tartour et al (1995) reported a significant decrease in CD3 zeta
chain expression in 4 out of 13 tumour-infiltrating lymphocytes
(TILs) derived from renal cell carcinoma. This defect was not found
after culturing TILs with IL-2. Similar results were obtained by
Rabinowich et al (1996) in T lymphocytes obtained from mela-
noma-involved lymph nodes. In another two studies (Matsuda et al,
1995; Yoong and Adams, 1998), normalization of the level of zeta
expression in colorectal cancer TIL cultures in the presence of rIL-2
has been observed. However, decreased expression of CD3 zeta was
not reversed by immunotherapy with IL-2 at low or high doses in
patients with melanoma (Rabinowich et al, 1996) or renal cell
cancer carcinoma (Farace et al, 1994), although in some patients
who achieved clinical response the initially reduced expression of
zeta normalized following IL-2 therapy (Rabinowich et al, 1996). In
a recent study, Guarini et al (1997) reported that transferring the 
IL-2 gene into the DNA of human cancer cells is capable of restoring
and maintaining the expression of CD3 zeta and other molecules
involved in the process of T cell-mediated tumour recognition. 
In our study, anti-CD3+rIL-2 stimulation of PBLs obtained from
patients with active HD significantly increased the proportion of
CD4+/zeta+, CD8+/zeta+ and CD56+/zeta cells. However, the level
of zeta chain expression remained significantly lower than that
found in the control subjects. These findings suggest that, in active
HD, the signal-transduction machinery is more profoundly
impaired than in other malignancies, since stimulation with 
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Table 2 CD3/zeta chain expression in unstimulated, anti-CD3 MoAb stimulated and anti-CD3 MoAb + rIL-2 stimulated peripheral
blood CD8+ cells from patients with Hodgkin’s disease in active phase of HD, complete remission and healthy controls 
Unstimulated Anti-CD3 MoAb Anti-CD3 MoAb+IL-2 P
stimulated stimulated
Active disease n = 20 60% ± 8% 65% ± 10% 72% ± 11% I:VII = 0.05  
(I) (IV) (VII) I:IV NS
IV:VII NS 
Clinical remission n = 15 69% ± 10% 74% ± 9% 88% ± 13%  II:VIII = 0.02 
(II) (V) (VIII) II:V NS
V:VIII NS 
Healthy controls n = 20 80% ± 10% 87% ± 12% 89% ± 10% III:IX = 0.05
(III) (VI) (IX) III:VI NS 
VI:IX NS 
P I:II NS IV:VI = 0.04 VII:VIII NS 
I:III = 0.05 V:VI = 0.05 VII:IX 0.05 
II:III = 0.05 IV:V NS VIII: IX NS 
Table 3 CD3/zeta chain expression in unstimulated, anti-CD3 MoAb stimulated and anti-CD3 MoAb + rIL-2
stimulated peripheral blood CD56+ cells from patients with Hodgkin’s disease in active phase of HD, complete
remission and healthy controls 
Unstimulated Anti-CD3 MoAb Anti-CD3 MoAb+IL-2  P
stimulated stimulated
Active disease n = 20 70% ± 8% 72% ± 14% 81% ± 10% I:VII = 0.02
(I) (IV) (VII) I: IV NS 
IV:VII NS 
Clinical remission n = 15 81% ± 12% 82% ± 20% 88% ± 11% II:VIII NS
(II) (V) (VIII) II: V NS 
V:VIII NS 
Healthy controls n = 20 85% ± 10% 89% ± 12% 92% ± 8% III:IX NS
(III) (VI) (IX) III:VI NS 
VI:IX NS 
P I:III = 0.05 IV:VI = 0.05 VII:IX = 0.05 
I:II NS  IV:V NS VII:VIII NS
II:III NS V:VI = 0.05  VIII:IX NS anti-CD3+rIL-2 only partially restored the defective zeta expres-
sion (Matsuda et al, 1995; Tartour et al, 1995; Rabinowich et al,
1996; Yoong and Adams, 1998). In clinical remission, only CD8+
cells showed decreased zeta chain expression, which normalized
after anti-CD3+rIL-2 stimulation. Our results showed that not all
lymphocytes obtained from cancer patients are equally affected
and that only some T immune cells could be rescued from a
tumour-induced down-regulation of signalling molecules. Accord-
ing to current knowledge it is difficult to ascertain whether IL-2
induces the expansion of lymphocytes with a normal zeta/epsilon
ratio or whether it regulates zeta expression. 
However, the fact that the reversion took place rapidly (72
hours) favours the interpretation that zeta negative cells can
rapidly normalize their altered CD3 complexes. As a functional
correlate of the decreased zeta expression in HD, we studied the
production of IL-2 by PBMC stimulated with anti-CD3+ rIL-2 in
patients in the active disease and in clinical remission as compared
with healthy subjects. 
In our patients in active HD, stimulation with anti-CD3+rIL-2
did not restore IL-2 production to normal levels, probably
reflecting the persistence of a decreased proportion of CD4/zeta+
and CD16+/zeta+ cells. In clinical remission, anti-CD3+rIL-2 stim-
ulation normalized the previously decreased zeta chain expression
in CD8+ cells, which probably resulted in normal IL-2 production.
This finding provides indirect support for a possible clinical use of
rIL-2 to prolong remission duration. 
Similar results were obtained by Zea et al (1995), who found
normal IL-2 production in patients with normal CD3 zeta status,
but this has not been confirmed by others. Tartour et al (1995)
found no correlation between IL-2 production and zeta expression
in TILs and PBLs obtained from patients with renal cell carci-
noma; however, the small number of patients tested does not allow
drawing definite conclusions. 
In summary, we have shown that rIL-2 partially restored
impaired CD3 zeta expression in CD4+, CD8+ and CD56+ cells and
normalized the proportion of CD8+/zeta+ expression in cells from
patients in clinical remission, which probably resulted in normal
IL-2 production in these patients. Considering the pivotal role of
CD3 zeta in the immune response, our data suggest that other
immunotherapeutic approaches could be considered in HD,
including the use of other cytokines and vaccinations with geneti-
cally engineered tumour vaccines. 
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